Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed advanced ovarian epithelial carcinoma
with greater than 1 cm residual disease at completion of initial surgery Stage IIB, IIIA,
IIIB, IIIC, or IV Measurable disease OR CA 125 greater than 120 units/mL obtained post
surgery

PATIENT CHARACTERISTICS: See General Eligibility Criteria

PRIOR CONCURRENT THERAPY: Biological therapy: No prior or concurrent immunotherapy
Chemotherapy: No prior or concurrent chemotherapy Endocrine: No prior or concurrent
hormonal therapy Radiotherapy: No prior radiotherapy No concurrent radiotherapy except to
limited fields (e.g., for palliation of bone pain) Surgery: Diagnostic surgery performed
less than 12 weeks prior to study No concurrent interval debulking Other: At least 30 days
or five half-lives since any prior investigational therapy No other concurrent
investigational therapy --Patients Characteristics-- Age: 18 and over Performance status:
ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: Hemoglobin at least 9.0 g/dL
WBC at least 4,000/mm3 Neutrophil count at least 1,500/mm3 Platelet count at least
100,000/mm3 Hepatic: SGOT and/or SGPT no greater than 2.5 times upper limit of normal
(ULN) (no greater than 5 times ULN if liver metastases present) Alkaline phosphatase no
greater than 2.5 times ULN (no greater than 5 times ULN if liver and/or bone metastases
present) Renal: Creatine less than 2 times ULN Creatinine clearance at least 50 mL/min
Other: No prior malignancy except basal cell skin carcinoma or carcinoma in situ of the
cervix No uncontrolled infection No other concurrent medical conditions that would prevent
full compliance or expose patient to extreme risk or decreased life expectancy No
concurrent medical condition for which treament with platinum compounds is contraindicated
No history of allergy to compounds related to the drugs used in this study No prior motor
or sensory neurotoxicity grade 2 or worse Not pregnant or nursing Fertile patients must
use effective contraception